AI Drug Discovery for GLP-1

AI drug discovery platforms, including Recursion Pharmaceuticals and Insilico Medicine, deployed large chemical language models to identify novel GLP-1 receptor agonists at a fraction of the cost of Ozempic and Wegovy—yielding a 60% reduction in manufacturing expenses versus #8's traditional methods. The first AI-discovered obesity treatment entered Phase II trials in 2025, compressing a 12-year development cycle to under 3. This approach boasts a 90% clinical trial success rate, outperforming the industry average of 14% and promising affordable alternatives for the 650 million obese adults globally.